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journal homepage: http: / /www.kjms-onl ine.comLETTER TO THE EDITORTorsade de pointes induced by amiodarone in a
patient with heart failureDear Editor,
Amiodarone is widely used to control and prevent the
occurrence of cardiac arrhythmias in patients with severe
heart failure. Although amiodarone, like other class III
antiarrhythmic drugs, can cause QT-interval prolongation,
the development of torsade de pointes (TdP) in patients
taking amiodarone is rare [1]. When fatal ventricular
arrhythmia occurs in a patient with severe heart failure
who is being treated with amiodarone, it is important
to determine whether the mechanism of ventricular
arrhythmia was induced by that drug or by other causes of
abnormal electrical activity in the heart.
A 61-year-old woman with severe mitral valve regurgi-
tation, atrial fibrillation, and heart failure under regular
medical control presented with progressive acute decom-
pensated heart failure. Mitral valve replacement (MVR) was
suggested. The results of 12-lead electrocardiography
revealed a QT interval of 450 ms and a corrected QT (QTc)
interval of 439 ms. MVR surgery was successfully per-
formed; however, amiodarone 300 mg administered as an
intravenous bolus followed by 900 mg/day administered as
an intravenous drip was required to treat a frequently
occurring premature ventricular contraction. After 2 days
of amiodarone therapy, 12-lead electrocardiography
revealed a QT interval of 520 ms and a QTc interval of
580 ms, respectively (Fig. 1A). A sustained, wide QRS
complex tachycardia with shifting axis was noted (Fig. 1B).
A diagnosis of TdP was made based on the presence of
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lead electrocardiography performed 5 days after discon-
tinuation of amiodarone revealed a QT interval of 440 ms
and a QTc interval of 519 ms and no evidence of a sustained
wide QRS complex tachycardia.
TdP is a lethal polymorphic ventricular tachycardia
characterized by prolonged QT intervals. Although amio-
darone is a class III antiarrhythmic agent, it has multiple
channel blocking effects, including blockade of the fast
sodium channel, the slow calcium channel, the delayed
outward potassium channels, and noncompetitive b-
adrenergic antagonism. Amiodarone therapy contributes
to approximately 2% of cases of incident proarrhythmic
events and to approximately 0.7% of cases of TdP [1]. The
low incidence of amiodarone-induced TdP may be because
amiodarone results in more homogeneous repolarization
across ventricular cells than other class III antiarrhythmic
drugs [2]. Older age, female sex, hypokalemia, and com-
bined use of amiodarone with digitalis therapy are inde-
pendent risk factors for TdP occurrence in patients under
amiodarone therapy [3]. In our patient, amiodarone was
used to treat premature ventricular contraction and
digoxin was used to treat atrial fibrillation and heart
failure. Combination therapy comprising digitalis drugs
and amiodarone can trigger bradycardia or a pause that
can trigger TdP [4]. In addition, digoxin can inhibit the
sodium/potassium pump, which can indirectly enhance
the sodium/calcium exchanger function, leading to
intracellular calcium accumulation and early after-
depolarizations [5].ed by Elsevier Taiwan LLC. All rights reserved.
Figure 1. (A) The 12-lead electrocardiogram after amio-
darone therapy. The QT interval is 520 ms and the corrected QT
interval is 580 ms. (B) A wide QRS tachycardia is noted after
aminodarone therapy recorded by bed-side eletrocardiogram
monitor. TdP is diagnosed based on the presence of prolonga-
tion of QT intervals and shifting axis.
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antiarrhythmic agent. Although the incidence of TdP is low,
amiodarone can induce TdP in patients with hypokalemia or
hypomagnesaemia and in patients who take the drug in
combination with digitalis therapy.
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